文献速递头颈与中枢神经肿瘤胸部肿瘤

切除性脑转移瘤术后管理:何时可推迟放疗?

Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?
PubMed 文献 · J Clin Oncol · 2018-10-08

本文通过一例67岁IIIB期非小细胞肺癌(NSCLC)患者,经手术切除小脑转移灶后仍有三处小脑外转移灶及残留瘤床,探讨了术后放疗的延迟时机。文章综述相关文献并给出作者建议的管理方法,以帮助临床医生将关键研究结果应用于实践。

要点

  • 术后MRI显示残留瘤床约3.7cm及三处≤1.2cm转移灶,需评估局部复发风险。
  • 患者ECOG PS 0、MMSE 29/30,无神经症状,为推迟放疗提供条件。
  • 文章探讨在残留病灶小且无占位效应时,可考虑推迟术后放疗。

核心结论

  • 对于切除性脑转移瘤患者,若术后残留病灶小且无占位效应,可考虑推迟放疗,但需个体化评估风险。

研究设计与样本

  • 本文为Oncology Grand Rounds系列文章,通过病例展示结合文献综述,讨论术后放疗延迟的临床决策。

主要发现

  • 病例为67岁女性NSCLC患者,小脑转移灶切除后有三处≤1.2cm残留病灶及约3.7cm残留瘤床,无占位效应。

关键数值与推荐

  • 患者术后ECOG PS 0,MMSE 29/30,无神经症状,未用激素及抗癫痫药。

临床怎么用

  • 临床实践中,对于术后残留病灶小、无占位效应且一般状况好的患者,可考虑推迟放疗并密切随访。

局限性

  • 本文为病例讨论与文献综述,非前瞻性研究,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 67-year-old woman was diagnosed 17 months ago with stage IIIB non-small-cell lung cancer (NSCLC; adenocarcinoma), without a targetable mutation, for which she received chemotherapy and thoracic radiotherapy. She developed new-onset gait ataxia, nausea, morning emesis, and headaches. A brain magnetic resonance imaging (MRI) scan demonstrated a 3.2-cm left cerebellar enhancing metastatic lesion, with surrounding vasogenic edema and mass effect, and three additional enhancing cortical, parenchymal lesions, each < 1.2 cm in maximum diameter, and none with significant mass effect ( Fig 1A ). A restaging positron emission tomography scan revealed no new sites of metastatic disease and no obvious intrathoracic progression. She underwent craniotomy, with piecemeal resection of the cerebellar metastatic lesion that proved to be recurrent lung cancer ( Fig 1B ). Her medical history was significant for mild hypertension and diet-controlled type II diabetes. She had smoked one pack a day for 32 years and had quit 3 years earlier. Postoperatively, her neurologic symptoms resolved, and physical and neurologic examinations were unrevealing; she had an Eastern Cooperative Oncology Group performance status (PS) of 0 and a Mini-Mental State Examination (MMSE) score of 29 of 30. A 3-week postoperative MRI scan confirmed the presence of 1-cm right frontal, 1.2-cm right parietal, and 1.2-cm left temporal enhancing lesions with minimal enhancement and no evidence of mass effect or edema. In addition, there was an ill-defined residual tumor bed, estimated to be approximately 3.7 cm in maximum diameter ( Fig 1C ). The patient was no longer receiving any steroids and was not receiving any anticonvulsants. Because of the residual three brain metastatic lesions, as well as the consideration of a high risk of surgical failure, she was referred for radiotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mehta MP, Kotecha R. Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred? J Clin Oncol. 2018. PMID: 30296192. doi:10.1200/JCO.2018.79.3232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。